麻豆传媒

In this exclusive 麻豆传媒 video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations in medicine.

The video was recorded at the recent American Society of Clinical Oncology (ASCO) meeting. Following is a transcript of his remarks:

I think that this change to subcutaneous formulations is something we're going to see as a larger trend in medicine. We've already seen applications for approval of a subcutaneous form of atezolizumab [Tecentriq], and we've already seen other subcutaneous formulations of drugs like Rituxan [rituximab] and drugs like Herceptin [trastuzumab].

We know that this is a formulation change that's going to be happening for more and more monoclonal antibodies because the technology that underlies the change in the formulation is largely the same for most of these products, and it's something that's good for patients. Patients by far prefer subcutaneous medication delivery to intravenous delivery.

And so anything we can do to make life better for our patients is something we should pursue, and I look forward to seeing more and more medications change to this route of delivery.

Comment